BioCentury
ARTICLE | Financial News

Digital therapeutics company Pear closes $64M series C round

January 4, 2019 10:26 PM UTC

Pear Therapeutics Inc. (Boston, Mass.) raised $64 million in a series C round to support commercialization of its reSET digital therapeutic portfolio and fund its clinical pipeline.

In November, Pear and partner Sandoz Ltd. launched in the U.S. reSET, the first FDA-authorized digital prescription therapeutic, to treat substance abuse disorder. Last month, FDA approved a second digital therapeutic from the partners, reSET-O, to treat opioid abuse disorder (see "A Year of Digital Progress at Novartis")...

BCIQ Company Profiles

Pear Therapeutics Inc.